SUMMARY Significant neurotoxicity including seizures, encephalopathy and coma may complicate the use of cyclosporin A (CyA). Two patients are described, receiving CyA, who presented with abnormal behaviour, stupor, focal motor activity and were shown to be in complex partial status epilepticus (CPSE) 
C3-CHIl 16 The blood levels of CyA in both patients were within the therapeutic range; metabolites of cyclosporin were not measured. Although the most serious neurotoxicity has been associated with CyA levels above the upper limit of the therapeutic range,258 neurological dysfunction has been seen in patients in whom the level of CyA was within the accepted therapeutic range.'7 However, it is possible that one or more of the metabolites of CyA may be responsible for the neurological toxicity of the drug. 
